Tarsus Pharmaceuticals will host a webcast on February 25, 2025, to discuss 2024 financial results and updates.
Quiver AI Summary
Tarsus Pharmaceuticals, Inc. announced that it will host a live webcast on February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET to discuss its fourth quarter and full-year 2024 financial results, along with a corporate update. The webcast will be accessible online, and a recorded version will be made available shortly after the event, archived for around 90 days. Tarsus focuses on innovative treatments, particularly in eye care, with FDA approval for XDEMVY® for the treatment of Demodex blepharitis and ongoing development of TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention.
Potential Positives
- Tarsus Pharmaceuticals is hosting a live webcast to report its fourth quarter and full-year 2024 financial results, indicating transparency and engagement with investors.
- The company is advancing a pipeline aimed at addressing diseases with high unmet needs, which could position it favorably within the healthcare market.
- XDEMVY® is FDA approved for the treatment of Demodex blepharitis, showcasing the company's capability in bringing products to market and meeting patient needs in eye care.
- Tarsus is developing additional treatments (TP-04 and TP-05) for Ocular Rosacea and Lyme disease prevention, reflecting innovation and expansion into diverse therapeutic areas.
Potential Negatives
- Despite announcing a webcast to discuss financial results, the lack of any detailed financial performance cues leading into the event raises concerns about potential underperformance in Q4 2024.
- The press release does not provide any indication of sales figures or market reception for their FDA-approved product, XDEMVY®, suggesting possible challenges in product uptake.
- The absence of updates on other products in their pipeline may indicate stagnation or difficulties in development, which could negatively impact investor confidence.
FAQ
When is Tarsus Pharmaceuticals' webcast for the fourth quarter results?
Tarsus Pharmaceuticals will host the webcast on February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET.
How can I access the Tarsus Pharmaceuticals webcast?
Participants can access the webcast through the link provided in the press release.
Will a recording of the Tarsus webcast be available?
Yes, a recorded version of the call will be available shortly after the webcast and archived for 90 days.
What is XDEMVY® and its approval status?
XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved for the treatment of Demodex blepharitis.
What other treatments is Tarsus Pharmaceuticals developing?
Tarsus is developing TP-04 for Ocular Rosacea and TP-05 for the prevention of Lyme disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TARS Hedge Fund Activity
We have seen 108 institutional investors add shares of $TARS stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 1,909,228 shares (+inf%) to their portfolio in Q4 2024, for an estimated $105,713,954
- PERCEPTIVE ADVISORS LLC removed 1,109,754 shares (-85.6%) from their portfolio in Q4 2024, for an estimated $61,447,078
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 883,043 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $48,894,090
- LORD, ABBETT & CO. LLC added 685,111 shares (+115.2%) to their portfolio in Q4 2024, for an estimated $37,934,596
- VIVO CAPITAL, LLC removed 565,550 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $18,600,939
- J. GOLDMAN & CO LP removed 427,305 shares (-76.6%) from their portfolio in Q4 2024, for an estimated $23,659,877
- IKARIAN CAPITAL, LLC removed 422,588 shares (-41.0%) from their portfolio in Q4 2024, for an estimated $23,398,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
Participants may access the webcast here . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY
®
(lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of
Demodex
blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
[email protected]
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
[email protected]
